

# Peter M Izmirly

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/212793/peter-m-izmirly-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70  
papers

3,905  
citations

28  
h-index

62  
g-index

95  
ext. papers

5,425  
ext. citations

7.2  
avg, IF

5.3  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 70 | 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412   | 9.5  | 488       |
| 69 | 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159   | 2.4  | 344       |
| 68 | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. <i>Circulation</i> , <b>2012</b> , 126, 76-82  | 16.7 | 280       |
| 67 | Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 85-88   | 59.2 | 278       |
| 66 | Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. <i>Circulation</i> , <b>2011</b> , 124, 1927-35   | 16.7 | 202       |
| 65 | Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1138-46                       |      | 176       |
| 64 | Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1827-30 | 2.4  | 164       |
| 63 | Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. <i>Nature Immunology</i> , <b>2019</b> , 20, 915-927  | 19.1 | 152       |
| 62 | The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 301-12  | 8.1  | 140       |
| 61 | Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. <i>JCI Insight</i> , <b>2017</b> , 2,  | 9.9  | 114       |
| 60 | Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 3091-7  |      | 107       |
| 59 | Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1153-7   |      | 99        |
| 58 | Mortality in Systemic Lupus Erythematosus: an Updated Review. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 21   | 4.9  | 84        |
| 57 | Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 137-56  | 5.1  | 83        |
| 56 | The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2006-2017   | 9.5  | 78        |
| 55 | Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1339-1344   | 2.4  | 78        |
| 54 | Neonatal lupus syndromes. <i>Rheumatic Disease Clinics of North America</i> , <b>2007</b> , 33, 267-85, vi   | 2.4  | 74        |

|    |   |      |    |
|----|---|------|----|
| 53 | Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. <i>Rheumatology</i> , <b>2012</b> , 51, 1086-92  | 3.9  | 73 |
| 52 | COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1981-1989                 | 9.5  | 66 |
| 51 | Prevention and treatment in utero of autoimmune-associated congenital heart block. <i>Cardiology in Review</i> , <b>2014</b> , 22, 263-7  | 3.2  | 64 |
| 50 | Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1161-5                             | 2.4  | 59 |
| 49 | Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,  | 9.5  | 39 |
| 48 | Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 292-302   | 15.1 | 38 |
| 47 | Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 466-72   | 5.3  | 37 |
| 46 | Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1971-1980   | 9.5  | 35 |
| 45 | Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 384-394  | 6.4  | 34 |
| 44 | A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity. <i>Science Translational Medicine</i> , <b>2018</b> , 10,   | 17.5 | 31 |
| 43 | Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1373-81                    | 4.7  | 31 |
| 42 | Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 545-551             | 5.3  | 28 |
| 41 | Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1742-1749  | 2.4  | 28 |
| 40 | Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 991-996            | 9.5  | 25 |
| 39 | A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 1074-1082            | 6.1  | 24 |
| 38 | Integrated urine proteomics and renal single-cell genomics identify an IFN- $\gamma$ response gradient in lupus nephritis. <i>JCI Insight</i> , <b>2020</b> , 5,  | 9.9  | 23 |
| 37 | Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 467-472  | 5.3  | 22 |
| 36 | Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 930-9 | 15.1 | 22 |

|    |   |      |    |
|----|---|------|----|
| 35 | A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 374-382  | 6.1  | 20 |
| 34 | The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 949-960   | 4.7  | 19 |
| 33 | Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. <i>Rheumatology</i> , <b>2009</b> , 48, 513-9   | 3.9  | 19 |
| 32 | Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 980-983  | 13.6 | 18 |
| 31 | Systemic Autoimmune Disease Among Adults Exposed to the September 11, 2001 Terrorist Attack. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 849-859  | 9.5  | 17 |
| 30 | Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339  | 2.4  | 16 |
| 29 | Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,  | 16.6 | 14 |
| 28 | Autoimmune-mediated congenital heart block. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 64, 41-51  | 4.6  | 14 |
| 27 | Rapid aneurysm growth and rupture in systemic lupus erythematosus. <i>Surgical Neurology International</i> , <b>2015</b> , 6, 9   | 1    | 13 |
| 26 | Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease <b>2021</b> ,   |      | 12 |
| 25 | SLE: reconciling heterogeneity. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000280  | 4.6  | 12 |
| 24 | Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e585-e594  | 14.2 | 11 |
| 23 | European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,   | 2.4  | 10 |
| 22 | Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000344  | 4.6  | 8  |
| 21 | Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 191   | 5.7  | 8  |
| 20 | Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials." by Gleicher N, Elkayam U, <i>Autoimmun Rev.</i> 2013 Sep;12(11):1039-45. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 70-2 | 13.6 | 7  |
| 19 | In search of an antibody specificity highly predictive of congenital heart block. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000154  | 4.6  | 6  |
| 18 | Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 233-242   | 4.7  | 6  |

|    |   |     |   |
|----|---|-----|---|
| 17 | Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008686                                   | 6.4 | 6 |
| 16 | Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 785-790 | 9.5 | 5 |
| 15 | Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , <b>2019</b> , 58, 2000-2008   | 3.9 | 5 |
| 14 | Validation of Systemic Lupus Erythematosus Diagnosis as the Primary Cause of Renal Failure in the US Renal Data System. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 599-604                              | 4.7 | 5 |
| 13 | Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 510-5  | 4.1 | 5 |
| 12 | No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 857-859  | 2.2 | 4 |
| 11 | SLE clinical trials: impact of missing data on estimating treatment effects. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000348   | 4.6 | 4 |
| 10 | Neonatal Lupus <b>2014</b> , 251-272  |     | 3 |
| 9  | Factors associated with long-term cardiac dysfunction in neonatal lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 217-224  | 2.4 | 3 |
| 8  | Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000266  | 4.6 | 3 |
| 7  | Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,                                    | 4.6 | 2 |
| 6  | Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. <i>Life Science Alliance</i> , <b>2021</b> , 4,  | 5.8 | 2 |
| 5  | Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,  | 9.5 | 1 |
| 4  | Neonatal Lupus <b>2019</b> , 486-498  |     | 1 |
| 3  | Neonatal Lupus <b>2016</b> , 451-461  |     | 0 |
| 2  | Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment <b>2021</b> , 507-519  |     |   |
| 1  | Passively acquired lupus in the fetus and neonate <b>2021</b> , 325-363   |     |   |